After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy’s Alfasigma – FiercePharma

by

  1. After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy’s Alfasigma FiercePharma
  2. Intercept, once a biotech trailblazer, sells itself for less than $1 billion STAT
  3. Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases Yahoo Finance
  4. Why Intercept Pharmaceuticals Stock Is Skyrocketing Today The Motley Fool
  5. Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today? InvestorPlace
  6. View Full Coverage on Google News

Read original article here

Leave a Comment